Today on Pharmaceutical Processing
For the sake of sustainability, put people at your core
It’s no secret the pharmaceutical industry has been slow to adopt sustainability practices. Unlike other industries, end users haven’t demanded products be made “greener.” In manufacturing, sustainability is still considered a cost rather than an investment. New technologies and innovative solutions may promise to deliver results, but many take years to show any return. In…
Eli Lilly to invest $450M in North Carolina diabetes treatment manufacturing facility
Eli Lilly (NYSE:LLY) announced today that it plans to invest an additional $450 million at a North Carolina manufacturing facility. Lilly expects the investment to create at least 100 new jobs at the Research Triangle Park, North Carolina, plant. Its expansion includes additional parenteral filling, device assembly and packaging capacity. Indianapolis-based Lilly said this expansion supports…
Sponsored Content See More >
A new way to access scientific papers?Losing university access doesn’t mean losing access to articles anymore By DeepDyve Digital Library Team Many researchers are surprised to…
Anti-idiotype Antibodies: A Powerful Weapon for PK/ADA AssaysBy Sino Biological Therapeutic monoclonal antibodies have emerged as the fastest-growing class of therapeutics since the mid-1980s from the increasing…
Noble expands its services for its clients into Human FactorsHuman Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug…
Regulatory See More >
FDA ordered to ramp up unannounced foreign inspections
The omnibus spending bill recently signed by President Joe Biden directs the FDA to expand unannounced foreign facility inspections and evaluate them through a new pilot program. The legislation includes $10 million for the program and a mandate to increase unannounced surveillance inspections of foreign drug establishments, Regulatory Focus reports. The legislation also directs the…
Facility See More >
Agilent spends $725M to expand manufacturing
Agilent recently announced that it plans to double its manufacturing capacity of therapeutic nucleic acids. The $725 million investment will go toward the Santa Clara, California–based company’s Frederick, Colorado facility. The Colorado plant will get new Train C and D manufacturing lines. The facility already has a Train B manufacturing line, announced in 2020, that…
Supply Chain See More >
Cardinal Health, Palantir partner on AI for pharmaceutical products
Cardinal Health (NYSE:CAH) announced that it entered into a strategic collaboration with Palantir Technologies (NYSE:PLTR). The partnership pairs the companies to design a solution to give health systems and hospitals dynamic purchase decision insights. These insights help them quickly improve their bottom line. Dublin, Ohio-based Cardinal Health plans to integrate this solution into Foundry, Palantir’s…
Recalls See More >
10 prominent drugs recalled over nitrosamines
In recent years, a number of drug companies have carried out prominent recalls of hypertension, heartburn and diabetes medications due to the presence of nitrosamines, organic compounds shown to cause cancer in animal studies. The problem could cost Big Pharma companies billions of dollars, but proving the cancer-causing role of nitrosamines in drugs may be difficult.…
